IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v11y2020i1d10.1038_s41467-020-18468-8.html
   My bibliography  Save this article

SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood

Author

Listed:
  • Dianna L. Ng

    (University of California, San Francisco
    University of California, San Francisco)

  • Gregory M. Goldgof

    (University of California, San Francisco)

  • Brian R. Shy

    (University of California, San Francisco)

  • Andrew G. Levine

    (University of California, San Francisco)

  • Joanna Balcerek

    (University of California, San Francisco)

  • Sagar P. Bapat

    (University of California, San Francisco)

  • John Prostko

    (Applied Research and Technology, Abbott Diagnostics)

  • Mary Rodgers

    (Applied Research and Technology, Abbott Diagnostics)

  • Kelly Coller

    (Applied Research and Technology, Abbott Diagnostics)

  • Sandra Pearce

    (Applied Research and Technology, Abbott Diagnostics)

  • Sergej Franz

    (Vitalant Research Institute)

  • Li Du

    (Vitalant Research Institute)

  • Mars Stone

    (University of California, San Francisco
    Vitalant Research Institute)

  • Satish K. Pillai

    (Vitalant Research Institute)

  • Alicia Sotomayor-Gonzalez

    (University of California, San Francisco
    UCSF-Abbott Viral Diagnostics and Discovery Center)

  • Venice Servellita

    (University of California, San Francisco
    UCSF-Abbott Viral Diagnostics and Discovery Center)

  • Claudia Sanchez San Martin

    (University of California, San Francisco
    UCSF-Abbott Viral Diagnostics and Discovery Center)

  • Andrea Granados

    (University of California, San Francisco
    UCSF-Abbott Viral Diagnostics and Discovery Center)

  • Dustin R. Glasner

    (University of California, San Francisco
    UCSF-Abbott Viral Diagnostics and Discovery Center)

  • Lucy M. Han

    (University of California, San Francisco
    University of California, San Francisco)

  • Kent Truong

    (University of California, San Francisco
    University of California, San Francisco)

  • Naomi Akagi

    (University of California, San Francisco
    University of California, San Francisco)

  • David N. Nguyen

    (University of California, San Francisco)

  • Neil M. Neumann

    (University of California, San Francisco)

  • Daniel Qazi

    (University of California, San Francisco)

  • Elaine Hsu

    (University of California, San Francisco)

  • Wei Gu

    (University of California, San Francisco)

  • Yale A. Santos

    (University of California, San Francisco
    UCSF-Abbott Viral Diagnostics and Discovery Center)

  • Brian Custer

    (Vitalant Research Institute)

  • Valerie Green

    (Creative Testing Solutions)

  • Phillip Williamson

    (Creative Testing Solutions)

  • Nancy K. Hills

    (University of California, San Francisco
    University of California, San Francisco)

  • Chuanyi M. Lu

    (University of California, San Francisco
    Laboratory Medicine Service, San Francisco VA Health Care System)

  • Jeffrey D. Whitman

    (University of California, San Francisco)

  • Susan L. Stramer

    (American Red Cross)

  • Candace Wang

    (University of California, San Francisco
    UCSF-Abbott Viral Diagnostics and Discovery Center)

  • Kevin Reyes

    (University of California, San Francisco
    UCSF-Abbott Viral Diagnostics and Discovery Center)

  • Jill M. C. Hakim

    (The Division of HIV, ID & Global Medicine)

  • Kirk Sujishi

    (University of California, San Francisco)

  • Fariba Alazzeh

    (University of California, San Francisco)

  • Lori Pham

    (University of California, San Francisco)

  • Edward Thornborrow

    (University of California, San Francisco)

  • Ching-Ying Oon

    (University of California, San Francisco)

  • Steve Miller

    (University of California, San Francisco
    UCSF-Abbott Viral Diagnostics and Discovery Center)

  • Theodore Kurtz

    (University of California, San Francisco)

  • Graham Simmons

    (University of California, San Francisco
    Vitalant Research Institute)

  • John Hackett

    (Applied Research and Technology, Abbott Diagnostics)

  • Michael P. Busch

    (University of California, San Francisco
    Vitalant Research Institute)

  • Charles Y. Chiu

    (University of California, San Francisco
    UCSF-Abbott Viral Diagnostics and Discovery Center
    University of California, San Francisco)

Abstract

Given the limited availability of serological testing to date, the seroprevalence of SARS-CoV-2-specific antibodies in different populations has remained unclear. Here, we report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seroreactivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors in early April 2020. We additionally describe the longitudinal dynamics of immunoglobulin-G (IgG), immunoglobulin-M (IgM), and in vitro neutralizing antibody titers in COVID-19 patients. The median time to seroconversion ranged from 10.3–11.0 days for these 3 assays. Neutralizing antibodies rose in tandem with immunoglobulin titers following symptom onset, and positive percent agreement between detection of IgG and neutralizing titers was >93%. These findings emphasize the importance of using highly accurate tests for surveillance studies in low-prevalence populations, and provide evidence that seroreactivity using SARS-CoV-2 anti-nucleocapsid protein IgG and anti-spike IgM assays are generally predictive of in vitro neutralizing capacity.

Suggested Citation

  • Dianna L. Ng & Gregory M. Goldgof & Brian R. Shy & Andrew G. Levine & Joanna Balcerek & Sagar P. Bapat & John Prostko & Mary Rodgers & Kelly Coller & Sandra Pearce & Sergej Franz & Li Du & Mars Stone , 2020. "SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood," Nature Communications, Nature, vol. 11(1), pages 1-7, December.
    • Handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18468-8
    DOI: 10.1038/s41467-020-18468-8
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-020-18468-8
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-020-18468-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Felix Dewald & Martin Pirkl & Martha Paluschinski & Joachim Kühn & Carina Elsner & Bianca Schulte & Jacqueline Knüfer & Elvin Ahmadov & Maike Schlotz & Göksu Oral & Michael Bernhard & Mark Michael & M, 2023. "Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients," Nature Communications, Nature, vol. 14(1), pages 1-13, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18468-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.